

# Anthony R Mato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1784396/publications.pdf>

Version: 2024-02-01

101  
papers

7,051  
citations

126907

33  
h-index

60623

81  
g-index

102  
all docs

102  
docs citations

102  
times ranked

7585  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: &lt;i>post-hoc&lt;/i> analyses from the phase III MURANO study. <i>Haematologica</i> , 2022, 107, 134-142.	3.5	11
2	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare). <i>Clinical Cancer Research</i> , 2022, 28, 603-608.	7.0	11
3	Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative Contributions. <i>Haematologica</i> , 2022, , .	3.5	1
4	Mechanisms of Resistance to Noncovalent Brutonâ€™s Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743.	27.0	87
5	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. <i>Drugs</i> , 2022, 82, 133-143.	10.9	6
6	A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib. <i>Haematologica</i> , 2022, 107, 2630-2640.	3.5	9
7	Long-term outcomes for ibrutinibâ€™rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	1.4	93
8	Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103696.	4.4	4
9	Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 581-583.	4.9	0
10	The potential of pirtobrutinib in multiple B-cell malignancies. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211016.	2.5	12
11	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	4.9	33
12	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3KÎ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
13	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2021, 5, 334-343.	5.2	32
14	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	13.7	260
15	All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia. <i>Haematologica</i> , 2021, 106, 2300-2301.	3.5	1
16	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Brutonâ€™s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 919-926.	4.3	7
17	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. <i>Leukemia and Lymphoma</i> , 2021, 62, 1940-1948.	1.3	7
18	Searching for a home: phosphoinositide 3â€™kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice. <i>British Journal of Haematology</i> , 2021, 194, 9-10.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	1.6	266
20	Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Brutonâ€™s Tyrosine Kinase Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 793-806.	2.2	1
21	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 174-183.e3.	0.4	21
22	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19
23	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
24	Approaches for relapsed CLL after chemotherapy-free frontline regimens. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 10-17.	2.5	8
25	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€‘world setting. A GIMEMAâ€™ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12
26	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5.	2.7	1
27	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
28	Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 3047-3049.	7.2	81
29	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARSâ€™CoVâ€™2â€™Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	2.7	18
30	BTK Inhibitors in Cancer Patients with COVID-19: â€‘The Winner Will be the One Who Controls That Chaosâ€™(Napoleon Bonaparte). <i>Clinical Cancer Research</i> , 2020, 26, 3514-3516.	7.0	36
31	Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 254-260.	2.3	11
32	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 438-444.e1.	0.4	18
33	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
34	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
35	Management of <sc>CLL</sc> patients early in the <sc>COVID</sc>â€™19 pandemic: An international survey of <sc>CLL</sc> experts. <i>American Journal of Hematology</i> , 2020, 95, E199-E203.	4.1	20
36	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Advances</i> , 2020, 4, 1407-1418.	5.2	12

#	ARTICLE	IF	CITATIONS
37	Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. <i>Cancer Discovery</i> , 2020, 10, 806-821.	9.4	73
38	COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. <i>Blood</i> , 2020, 136, 6-7.	1.4	4
39	Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 18-23.	2.5	8
40	Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry. <i>Blood</i> , 2020, 136, 42-43.	1.4	5
41	Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020, 136, 19-22.	1.4	0
42	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. <i>Cancer Discovery</i> , 2019, 9, 1452-1467.	9.4	60
43	Ibrutinib+Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	27.0	545
44	PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation. <i>PET Clinics</i> , 2019, 14, 405-410.	3.0	10
45	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
46	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. <i>Haematologica</i> , 2019, 104, 2258-2264.	3.5	26
47	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
48	Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Network Open</i> , 2019, 2, e1916326.	5.9	22
49	Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 442-448.	2.0	4
50	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. <i>Blood</i> , 2019, 133, 121-129.	1.4	18
51	Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. <i>Leukemia and Lymphoma</i> , 2019, 60, 955-963.	1.3	12
52	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
53	Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor. <i>Blood</i> , 2019, 134, 501-501.	1.4	23
54	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. <i>Blood</i> , 2019, 134, 4311-4311.	1.4	15

#	ARTICLE	IF	CITATIONS
55	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
56	Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. <i>Cancer Biology and Therapy</i> , 2018, 19, 1-2.	3.4	32
57	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 114-124.e2.	0.4	23
58	Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. <i>Cancer Biology and Therapy</i> , 2018, 19, 636-643.	3.4	13
59	Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reduced-dose ibrutinib: results from a multicentre study. <i>British Journal of Haematology</i> , 2018, 181, 259-261.	2.5	51
60	Biosimilars in Oncology in the United States. <i>JAMA Oncology</i> , 2018, 4, 241.	7.1	41
61	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	10.7	314
62	Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 580-591.	3.8	13
63	Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e421-e426.	0.4	9
64	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401.	4.1	52
65	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	2.5	37
66	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
67	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. <i>Blood</i> , 2018, 132, 298-298.	1.4	73
68	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7530-7530.	1.6	5
69	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2017, 377, 2545-2554.	27.0	1,390
70	Emerging Strategies in Treating Double Hit Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 563-568.	0.4	6
71	Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 113-121.	1.6	15
72	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	1.6	132

#	ARTICLE	IF	CITATIONS
73	Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. American Journal of Hematology, 2016, 91, 672-676.	4.1	27
74	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood, 2016, 128, 2199-2205.	1.4	166
75	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 1409-1418.	10.7	290
76	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. British Journal of Haematology, 2016, 175, 892-903.	2.5	42
77	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology, The, 2016, 17, 200-211.	10.7	373
78	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research, 2016, 22, 2684-2696.	7.0	157
79	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood, 2015, 126, 478-485.	1.4	37
80	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 2015, 90, 778-783.	4.1	71
81	Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. British Journal of Haematology, 2015, 170, 504-514.	2.5	140
82	The Graft-Versus-Myeloma Effect: Chronic Graft-Versus-Host Disease but Not Acute Graft-Versus-Host Disease Prolongs Survival in Patients with Multiple Myeloma Receiving Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1211-1216.	2.0	47
83	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood, 2014, 124, 2354-2361.	1.4	382
84	Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis. Blood, 2014, 124, 3056-3056.	1.4	1
85	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-17 Trial. Blood, 2014, 124, 327-327.	1.4	33
86	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. Blood, 2014, 124, 4697-4697.	1.4	11
87	A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen. Blood, 2014, 124, 4678-4678.	1.4	2
88	The Impact of Autoimmune Disease on Clinical Outcomes of Patients with DLBCL and FL. Blood, 2014, 124, 2974-2974.	1.4	0
89	Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. Blood, 2014, 124, 4672-4672.	1.4	0
90	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 2606-2612.	1.3	14

#	ARTICLE	IF	CITATIONS
91	First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3K $\gamma$ , In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies. <i>Blood</i> , 2013, 122, 678-678.	1.4	26
92	Liquid Tumors in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2012, 28, 115-152.	2.6	0
93	Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with RhyperCVAD. <i>Cancer</i> , 2012, 118, 3565-3570.	4.1	42
94	Elevation in serum lactate at the time of Febrile Neutropenia (FN) in hemodynamically-stable patients with Hematologic Malignancies (HM) is associated with the development of septic shock within 48 hours. <i>Cancer Biology and Therapy</i> , 2010, 9, 585-589.	3.4	28
95	Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. <i>Cancer Biology and Therapy</i> , 2009, 8, 1095-1100.	3.4	13
96	Comparison of Contrast-Enhanced CT, PET/CT, PET, and Low-Dose Non-Contrast Enhanced CT Imaging of Diffuse Large B-Cell, Follicular, Small Lymphocytic/CLL, and Marginal Zone Lymphomas.. <i>Blood</i> , 2009, 114, 1402-1402.	1.4	1
97	Novel strategies for relapsed and refractory acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2008, 15, 108-114.	2.5	24
98	Serum Lactic Acid (LA) as a Predictor of Septic Shock in Patients with Hematologic Malignancies (HM) Who Develop Febrile Neutropenia. <i>Blood</i> , 2008, 112, 666-666.	1.4	7
99	A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies.. <i>Blood</i> , 2007, 110, 2628-2628.	1.4	0
100	Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.. <i>Blood</i> , 2007, 110, 633-633.	1.4	1
101	A Predictive Model for Cytogenetic Risk Group in Elderly AML: The Penn Cytogenetic Surrogate Score (PCSS).. <i>Blood</i> , 2006, 108, 4446-4446.	1.4	0